JP Morgan Chase
BIOA

JP Morgan Chase’s BioAge Labs BIOA Stock Holding History

JP Morgan Chase’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.84M Buy
233,979
+60,409
+35% +$1.09M ﹤0.01% 3317
2026
Q1 		$2.75M Buy
173,570
+151,541
+688% +$2.92M ﹤0.01% 3860
2025
Q4 		$291K Sell
22,029
-14,819
-40% -$131K ﹤0.01% 5330
2025
Q3 		$217K Buy
36,848
+25,638
+229% +$120K ﹤0.01% 5471
2025
Q2 		$46.3K Sell
11,210
-3,012
-21% -$12.1K ﹤0.01% 5954
2025
Q1 		$53.5K Buy
14,222
+8,887
+167% +$41.1K ﹤0.01% 5857
2024
Q4 		$30.9K Sell
5,335
-194,665
-97% -$3.36M ﹤0.01% 6148
2024
Q3 		$4.16M Buy
+200,000
New +$4.01M ﹤0.01% 3347

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

JP Morgan Chase's BIOA Position: Q2 2026 in Review

JP Morgan Chase increased its BioAge Labs (BIOA) stake by 35% in Q2 2026, buying an estimated $1.09M and bringing the position to 233,979 shares worth $5.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

JP Morgan Chase first reported a position in BIOA in Q3 2024 and has held it in 8 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • JP Morgan Chase held 233,979 shares of BioAge Labs worth $5.84M as of Q2 2026.
  • JP Morgan Chase bought 60,409 BioAge Labs shares in Q2 2026, an estimated $1.09M.
  • BioAge Labs made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3317 holding.
  • JP Morgan Chase first reported a position in BioAge Labs in Q3 2024 and has held it in 8 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.